BridgeBio Pharma
BBIO
BBIO
357 hedge funds and large institutions have $8.15B invested in BridgeBio Pharma in 2025 Q2 according to their latest regulatory filings, with 92 funds opening new positions, 135 increasing their positions, 104 reducing their positions, and 34 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more first-time investments, than exits
New positions opened: | Existing positions closed:
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more capital invested
Capital invested by funds: $ → $
18% more funds holding
Funds holding: 302 → 357 (+55)
2.08% more ownership
Funds ownership: 97.36% → 99.44% (+2.1%)
6% less funds holding in top 10
Funds holding in top 10: 18 → 17 (-1)
Holders
357
Holding in Top 10
17
Calls
$515M
Puts
$105M
Top Buyers
| 1 | +$93.7M | |
| 2 | +$90.9M | |
| 3 | +$86.5M | |
| 4 |
D.E. Shaw & Co
New York
|
+$86.3M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$68.4M |
Top Sellers
| 1 | -$259M | |
| 2 | -$151M | |
| 3 | -$112M | |
| 4 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
-$82M |
| 5 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$33.3M |